Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter

High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing

(2014) R. Bourgon et al.   CLINICAL CANCER RESEARCH

Differences in DNA Methylation Signatures Reveal Multiple Pathways of Progression From Adenoma to Colorectal Cancer

(2014) Yanxin Luo et al.   GASTROENTEROLOGY

Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma

(2014) Shinji Kohsaka et al.   NEURO-ONCOLOGY

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

(2014) S. Rebouissou et al.   Science Translational Medicine

Epiregulin: Roles in normal physiology and cancer

(2014) David J. Riese et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

(2013) George Pentheroudakis et al.   BMC CANCER

High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor

(2013) Gregor Auf et al.   BMC CANCER

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

(2013) D J Jonker et al.   BRITISH JOURNAL OF CANCER

Increased TGF-  as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells

(2013) T. Troiani et al.   CLINICAL CANCER RESEARCH

Tumor fibroblast–derived epiregulin promotes growth of colitis-associated neoplasms through ERK

(2013) Clemens Neufert et al.   JOURNAL OF CLINICAL INVESTIGATION

Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?

(2013) Aaron R. Hansen et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia

(2013) Daniel J. DeAngelo et al.   LEUKEMIA RESEARCH

S100A4 interacts with p53 in the nucleus and promotes p53 degradation

(2013) L M Orre et al.   ONCOGENE

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK

(2013) Yong-Liang Yao et al.   PLoS One

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non-Small Cell Lung Cancer

(2012) K. Walter et al.   CLINICAL CANCER RESEARCH

TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis

(2012) Victoria R. Skeen et al.   CURRENT PHARMACEUTICAL DESIGN

Role of NF-κB in epithelial biology

(2012) Manolis Pasparakis   IMMUNOLOGICAL REVIEWS

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

(2012) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers

(2012) Jiyeon Yun et al.   LABORATORY INVESTIGATION

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia

(2012) E Lainey et al.   ONCOGENE

Molecular Genetics of Colorectal Cancer

(2011) Eric R. Fearon   Annual Review of Pathology-Mechanisms of Disease

Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis

(2011) Jun-Zhong Sun et al.   HEMATOLOGICAL ONCOLOGY

Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines

(2011) Goro Oshima et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

(2011) Timothy J. Price et al.   JOURNAL OF CLINICAL ONCOLOGY

5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer

(2010) Rodrigo Jover et al.   GASTROENTEROLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma

(2009) Gerusa G Seniski et al.   BMC CANCER

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

(2008) K. Yonesaka et al.   CLINICAL CANCER RESEARCH

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative lesion sequencing provides insights into tumor evolution

(2008) S. Jones et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA